By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AnGes MG Inc. 

Senri Life Science Center Building 10F
1-4-2
Shinsenri Higashi-machi  Toyonaka  560-0082  Osaka
Phone: 03-5730-2480 Fax:


SEARCH JOBS


Industry
Biotechnology

Segment
Pharmaceuticals





Company News
AnGes MG Inc. Enters Into the Definitive Agreement With Mitsubishi Tanabe Pharma Corporation for Exclusive Marketing Rights of Collategene® in the United States 10/24/2012 8:44:31 AM
Vical Incorporated (VICL) and AnGes MG Inc. Sign Letter of Intent for Pandemic Influenza Program 10/8/2008 9:39:12 PM
Vical Incorporated (VICL) and AnGes MG Inc. Sign Letter of Intent for Pandemic Influenza Program 10/8/2008 11:18:28 AM
Vical Incorporated (VICL) Receives $1 Million Milestone Payment From AnGes MG Inc. for Angiogenesis Program 7/22/2008 10:25:41 AM
AnGes MG Inc. Files NDA in Japan for Collategene Angiogenesis Product 3/28/2008 7:44:16 AM
Vical Incorporated (VICL) Receives Payment from AnGes MG Inc. for Allovectin-7(R) Phase 3 Pivotal Trial 1/17/2008 6:47:59 AM
AnGes MG Inc. Submits BLA to Japanese Ministry of Health 8/13/2007 8:16:59 AM
Vical Incorporated (VICL) Licensee AnGes MG Inc. Announces Positive Results of Phase 3 Angiogenesis Trial in Japan 6/18/2007 10:13:49 AM
AnGes MG Inc., Vical Incorporated (VICL) To Start Phase III Clinical Trial Of Allovectin For Gene Therapy 1/17/2007 12:13:18 PM
Vical Incorporated (VICL) Announces News Release And Conference Call Schedule To Discuss Collaborative Agreement With AnGes MG Inc. For Allovectin-7(R) 5/30/2006 11:12:48 AM
1234
//-->